2025
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trialsEfficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials.
Jaime-Casas S, Zugman M, Barragan-Carrillo R, Zang P, Ebrahimi H, Mercier B, Castro D, Yip W, Li X, Dizman N, Salgia N, Hsu J, Nguyen C, Chehrazi-Raffle A, Zengin Z, Meza L, Pal S, Tripathi A. Efficacy and toxicity profile of antibody-drug conjugate (ADC) based combination therapy in patients with advanced urothelial carcinoma (aUC): A systematic review of clinical trials. Journal Of Clinical Oncology 2025, 43: 813-813. DOI: 10.1200/jco.2025.43.5_suppl.813.Peer-Reviewed Original ResearchAny-grade adverse eventsAdvanced urothelial carcinomaObjective-response rateAntibody-drug conjugatesCombination regimensClinical trialsCheckpoint inhibitorsSafety/tolerability profileCombination therapyPublished prospective clinical trialsProspective clinical trialPeer-reviewed clinical trialsSystematic review of clinical trialsReview of clinical trialsRandom-effects modelEnfortumab vedotinSacituzumab govitecanUrothelial carcinomaProspective trialsTreatment landscapeMaculopapular rashEfficacy outcomesRetrospective studyToxicity profileCase reportSafety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS
Allegretti J, Feuerstadt P, Knapple W, Orenstein R, Pinton P, Sheh A, Khanna S. Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflammatory Bowel Diseases 2025, izae291. PMID: 39862395, DOI: 10.1093/ibd/izae291.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsRecurrent Clostridioides difficile infectionInflammatory bowel diseaseClostridioides difficile infectionWeeks of administrationPrevention of recurrent CDISerious treatment-emergent adverse eventsSubgroup analysisSustained clinical response ratesBowel diseaseSustained clinical responseClinical response rateModerate gastrointestinal symptomsUS Food and Drug AdministrationTreatment success rateFood and Drug AdministrationClinical responseSingle-doseProspective trialsFecal microbiotaEfficacy outcomesDifficile infectionAdverse eventsGastrointestinal symptomsTreatment success
2024
Saturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator
Mahal A, Yu J, Mahal R, Tien C, Adefres B, Damast S. Saturday, July 13, 202411:30 AM - 12:30 PMGSOR01 Presentation Time: 11:30 AM A Prospective Clinical Trial Assessing Comfort of Brachytherapy with a Novel Tapered Vaginal Applicator. Brachytherapy 2024, 23: s72-s73. DOI: 10.1016/j.brachy.2024.08.099.Peer-Reviewed Original ResearchVisual-analogue-scaleVaginal brachytherapyVaginal stretchingVaginal applicationEndometrial cancerAssociated with less painIr-192 seedsDose fall-offClinically significant responseProspective clinical trialPatient-centered evaluationVaginal introitusProspective trialsDose distributionSurface doseVaginal mucosaIr-192Less painNarrow introitusPaired t-testEC patientsConsenting patientsClinical trialsIntroitusPatientsPre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates
Jansen C, Pagadala M, Cardenas M, Prabhu R, Goyal S, Zhou C, Chappa P, Vo B, Ye C, Hopkins B, Zhong J, Klie A, Daniels T, Admassu M, Green I, Pfister N, Neill S, Switchenko J, Prokhnevska N, Hoang K, Torres M, Logan S, Olson J, Nduom E, del Balzo L, Patel K, Burri S, Asher A, Wilkinson S, Lake R, Kesarwala A, Higgins K, Patel P, Dhere V, Sowalsky A, Carter H, Khan M, Kissick H, Buchwald Z. Pre-operative stereotactic radiosurgery and peri-operative dexamethasone for resectable brain metastases: a two-arm pilot study evaluating clinical outcomes and immunological correlates. Nature Communications 2024, 15: 8854. PMID: 39402027, PMCID: PMC11473782, DOI: 10.1038/s41467-024-53034-6.Peer-Reviewed Original ResearchConceptsPre-operative stereotactic radiosurgeryCD8 T cellsEffector-like cellsT cellsStereotactic radiosurgeryBrain metastasesCD8 T cell responsesEndpoint of overall survivalDistant brain failureResected brain metastasesEfficacy of immunotherapyT cell responsesAntigen presenting cellsSecondary clinical endpointsLocal recurrenceLeptomeningeal diseaseOverall survivalImmune compositionProspective trialsImmune nichePrimary endpointImmunological correlatesPresenting cellsClinical outcomesPilot studyTemperature Control Parameters Are Important: Earlier Preinduction Is Associated With Improved Outcomes Following Out-of-Hospital Cardiac Arrest
Beekman R, Kim N, Nguyen C, McGinniss G, Deng Y, Kitlen E, Garcia G, Wira C, Khosla A, Johnson J, Miller P, Perman S, Sheth K, Greer D, Gilmore E. Temperature Control Parameters Are Important: Earlier Preinduction Is Associated With Improved Outcomes Following Out-of-Hospital Cardiac Arrest. Annals Of Emergency Medicine 2024, 84: 549-559. PMID: 39033449, DOI: 10.1016/j.annemergmed.2024.06.007.Peer-Reviewed Original ResearchOut-of-hospital cardiac arrestNeurological outcomeDevice cohortCardiac arrestOut-of-hospital cardiac arrest patientsConsecutive out-of-hospital cardiac arrestPreinduction timeInterquartile rangeAssociated with improved outcomesCardiac arrest patientsProportion of patientsMultivariate logistic regression modelInverse probability of treatmentDevice timeInverse probability treatment weightsProbability of treatmentProspective trialsOHCA patientsArrest patientsClinical outcomesLogistic regression modelsCenter studyEarly initiationSecondary outcomesTreatment weightingMolecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC).
Zaemes J, Hugaboom M, Shah V, Haas N, McDermott D, Jegede O, Bilen M, Stein M, Sosman J, Alter R, Plimack E, Hurwitz M, Wu C, Einstein D, Hammers H, Signoretti S, West D, Denize T, Atkins M, Braun D. Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo + ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC). Journal Of Clinical Oncology 2024, 42: 4546-4546. DOI: 10.1200/jco.2024.42.16_suppl.4546.Peer-Reviewed Original ResearchObjective response rateImmune checkpoint blockadeProgression-free survivalProgressive diseaseAnti-VEGFOverall survivalAssociated with higher progression-free survivalTumor samplesAdvanced clear cell renal cell carcinomaCombined immune checkpoint blockadeHigher progression-free survivalIncreased PFSImmune checkpoint blockade therapyShorter progression-free survivalClear cell renal cell carcinomaAnti-VEGF therapyCell renal cell carcinomaWeeks of therapyRenal cell carcinomaBiomarkers of efficacyFFPE tumor samplesNIVO monotherapyCheckpoint blockadeDecreased OSProspective trialsARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC).
Wainberg Z, Han S, Lee S, Lee K, Kopetz S, Mizrahi J, Hong Y, Ghiringhelli F, Italiano A, Tougeron D, Beagle B, Boakye M, Zhao T, Rhee J, Nuyten D, Cecchini M. ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2024, 42: 3508-3508. DOI: 10.1200/jco.2024.42.16_suppl.3508.Peer-Reviewed Original ResearchProgression-free survivalMetastatic colorectal cancerOverall survivalCohort BActivation of effector T cellsManagement of metastatic colorectal cancerAnti-PD-1 antibodyTreat metastatic colorectal cancerTreated with 5-FURandomized phase II clinical trialIrinotecan-containing regimensPhase Ib/II trialPhase II clinical trialEffector T cellsAdenosine receptor blockadeCohort of patientsII clinical trialsIrinotecan regimensMFOLFOX-6OS improvementReceptor blockadePrimary endpointProspective trialsReceptor antagonistSecondary endpointsPanic Disorder
Khasnavis S, Asghar-Ali A. Panic Disorder. 2024, 291-297. DOI: 10.1007/978-3-031-55711-8_22.Peer-Reviewed Original ResearchPanic disorderTreatment of panic disorderCognitive behavioral therapyOlder adultsBehavioral therapyPsychiatric reviewPhysical sensationsOnset episodesYoung adultsTreatment strategiesDisordersAppropriate treatment strategyAdultsNeurological conditionsProspective trialsPanicPharmacotherapyPatient preferencesWeighing risksFearTreatmentRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimodHigher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia
Ahmad A, Bromberg D, Shrestha R, Salleh N, Bazazi A, Kamarulzaman A, Shenoi S, Altice F. Higher methadone dose at time of release from prison predicts linkage to maintenance treatment for people with HIV and opioid use disorder transitioning to the community in Malaysia. International Journal Of Drug Policy 2024, 126: 104369. PMID: 38484531, PMCID: PMC11056294, DOI: 10.1016/j.drugpo.2024.104369.Peer-Reviewed Original ResearchMethadone maintenance treatmentNational Institute of Drug AbuseMethadone dosePost-releaseOpioid dependenceMaintenance treatmentMethadone maintenance treatment doseHigher doses of methadoneProspective trialsHighest methadone dosagePost-release outcomesHigher methadone dosesMalaysia’s largest prison.Levels of depressionTreatment of opioid use disorderMonths of releaseDose of methadoneOpioid use disorderLargest prisonHigher dosageIncarcerated peopleIncarceration periodUse disorderMethadone dosageTime-to-event analysis
2023
Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System
Kinslow C, Rae A, Kumar P, McKhann G, Sisti M, Bruce J, Yu J, Cheng S, Wang T. Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System. Cancers 2023, 15: 876. PMID: 36765837, PMCID: PMC9913704, DOI: 10.3390/cancers15030876.Peer-Reviewed Original ResearchNational Cancer DatabaseCause-specific survivalIntermediate-risk groupCentral nervous systemSolitary fibrous tumor/hemangiopericytomaAssociation of radiotherapyHigh-risk groupOverall survivalRisk categoriesRisk stratificationAssociated with improved survivalPrognostic risk categoriesGross-total resectionKaplan-Meier methodNervous systemCox proportional hazards regressionLow-risk groupProportional hazards regressionEORTC Cooperative GroupRadiotherapy strategiesSEER databaseSurvival benefitProspective trialsCancer DatabaseMeningeal tumors
2021
PILOT STUDY OF PERCUTANEOUS TEMPORARY DIAPHRAGM PACING WIRES IN CARDIAC SURGERY PATIENTS AT RISK OF PROLONGED MECHANICAL VENTILATION DURING THE COVID-19 PANDEMIC
Jarrett C, Onders R, Pelletier M, Abu-Omar Y, Baeza C, Elgudin Y, Markowitz A, Vega P, Sabik J. PILOT STUDY OF PERCUTANEOUS TEMPORARY DIAPHRAGM PACING WIRES IN CARDIAC SURGERY PATIENTS AT RISK OF PROLONGED MECHANICAL VENTILATION DURING THE COVID-19 PANDEMIC. Canadian Journal Of Cardiology 2021, 37: s112-s113. PMCID: PMC8523110, DOI: 10.1016/j.cjca.2021.07.213.Peer-Reviewed Original ResearchProlonged mechanical ventilationCardiac surgery patientsCardiac surgeryDiaphragm pacingMechanical ventilationDiaphragm functionSurgery patientsHigh-risk cardiac surgery patientsVentilator induced diaphragm dysfunctionRisk of prolonged mechanical ventilationDecreased ventilation timeLikelihood of extubationPrevent diaphragm atrophyHistory of TIAOpen heart surgeryProlonged mechanical ventilation patientsRelated adverse eventsOutcomes of DPDevice related adverse eventsRandomized controlled trialsDiaphragm atrophyDiaphragm dysfunctionProspective trialsMedian timeVentilation time
2020
Bioprosthetic valve oversizing is associated with increased risk of valve thrombosis following TAVR
Simpson T, Tuohy C, Rajotte K, Golwala H, Fuss C, Song H, Zahr F, Chadderdon S. Bioprosthetic valve oversizing is associated with increased risk of valve thrombosis following TAVR. Catheterization And Cardiovascular Interventions 2020, 97: e411-e417. PMID: 32633055, DOI: 10.1002/ccd.29104.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAssociated with increased riskHypoattenuated leaflet thickeningValve thrombosisValve oversizingRisk of valve thrombosisTranscatheter heart valve thrombosisEvaluated consecutive patientsAortic valve replacementInitiation of anticoagulationSevere aortic stenosisSAPIEN 3 valveSTS risk scoreStructural valve deteriorationAssociated with increased risk of strokeStudy of patientsValve-in-valveRisk of strokeRate of strokeConsecutive patientsProspective trialsValve replacementAortic stenosisLeaflet thickeningValve deteriorationUltrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysisAssociation of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program
Katzman J, Takeda M, Greenberg N, Balasch M, Alchbli A, Katzman W, Salvador J, Bhatt S. Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program. JAMA Network Open 2020, 3: e200117. PMID: 32101312, PMCID: PMC7137685, DOI: 10.1001/jamanetworkopen.2020.0117.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid treatment programsTreatment programsUse disorderOpioid overdose reversalOverdose reversalHistory of opioid use disorderStudy participantsTreated with methadoneOverdose educationStudy enrollment periodUnintentional opioid overdose deathsSubstance use disordersOpioid overdose-related deathsUS opioid crisisNaloxone distributionProspective trialsCohort studyNaloxoneOverdose-related deathsPositive historyOpioidPrimary outcomeOpioid overdose educationPrescribing naloxone
2019
Stereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Stereotactic Body Radiation Therapy Vs Hypofractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer (SHRAPNEL): An International Meta-Analysis of 24 Prospective Trials. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: e289. DOI: 10.1016/j.ijrobp.2019.06.1829.Peer-Reviewed Original Research
2017
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach
Shinder B, Rhee K, Farrell D, Farber N, Stein M, Jang T, Singer E. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Frontiers In Oncology 2017, 7: 107. PMID: 28620578, PMCID: PMC5449498, DOI: 10.3389/fonc.2017.00107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMetastatic renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaSurgical managementSurgical management of patientsImmune checkpoint inhibitorsNeoadjuvant systemic therapyMetastatic kidney cancerCytokine-based immunotherapyOptimal patient selectionManagement of patientsCheckpoint inhibitorsCytoreductive surgeryMetastatic diseasePrimary tumorAdjuvant therapyProspective trialsTherapeutic armamentariumPatient selectionKidney cancerTherapyCarcinomaSurgeryPatients
2016
Asthma outcomes after adenotonsillectomy: A systematic review
Kohli N, DeCarlo D, Goldstein N, Silverman J. Asthma outcomes after adenotonsillectomy: A systematic review. International Journal Of Pediatric Otorhinolaryngology 2016, 90: 107-112. PMID: 27729114, DOI: 10.1016/j.ijporl.2016.08.030.Peer-Reviewed Original ResearchConceptsMarkers of asthma severityObstructive sleep apneaEffect of adenoidectomySleep apneaAsthma severityPediatric populationAirway diseaseSystematic reviewAsthma outcomesUpper airway inflammationIncreased risk of asthmaUpper airway diseaseRespiratory medication useHistory of asthmaModulation of asthmaClinically significant reductionDevelopment of asthmaRisk of asthmaAsthma-related exacerbationsLower airway diseaseCraniofacial syndromesProspective trialsDecreased asthma severityAsthma-related symptomsSignificant comorbidities
2012
Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A
Auerswald G, Thompson A, Recht M, Brown D, Liesner R, Guzmán-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thrombosis And Haemostasis 2012, 107: 1072-1082. PMID: 22476554, PMCID: PMC6292131, DOI: 10.1160/th11-09-0642.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesDrug Administration ScheduleEthnicityEuropeFactor VIIIFemaleHemophilia AHemorrhageHemostasisHemostaticsHumansInfantInfant, NewbornLinear ModelsLogistic ModelsMaleNorth AmericaOdds RatioProspective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsMinimally treated patientsFamily history of inhibitorsHistory of inhibitorsRAHF-PFMBleeding episodesNon-Caucasian ethnicityUntreated patientsHaemostatic efficacyHemophilia AAdverse eventsHigh risk of inhibitor developmentFamily historySevere/moderately severe hemophilia ARisk of inhibitor developmentTreat bleeding episodesSevere hemophilia AAssociated with higher riskSevere hemophilia A.Prophylactic treatment regimensExposure daysInhibitor developmentPerioperative coverageRating surgeriesProspective trialsTreatment regimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply